Peter W. Rodino III, Esq., J.D.
Net Worth

Last updated:

What is Peter W. Rodino III, Esq., J.D. net worth?

The estimated net worth of Mr. Peter W. Rodino III, Esq., J.D. is at least $5,982,086 as of 6 May 2024. He owns shares worth $527,206 as insider and has received compensation worth at least $5,454,880 in AIM ImmunoTech Inc..

What is the salary of Peter W. Rodino III, Esq., J.D.?

Mr. Peter W. Rodino III, Esq., J.D. salary is $681,860 per year as Chief Operating Officer, Executive Director of Gov.al Relations, Gen. Counsel & Sec. in AIM ImmunoTech Inc..

How old is Peter W. Rodino III, Esq., J.D.?

Mr. Peter W. Rodino III, Esq., J.D. is 74 years old, born in 1951.

What stocks does Peter W. Rodino III, Esq., J.D. currently own?

As insider, Mr. Peter W. Rodino III, Esq., J.D. owns shares in one company:

Company Title Shares Price per share Total value
AIM ImmunoTech Inc. (AIM) Chief Operating Officer, Executive Director of Gov.al Relations, Gen. Counsel & Sec. 212,583 $2.48 $527,206

What does AIM ImmunoTech Inc. do?

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

AIM logo
AIM
AIM ImmunoTech Inc.
$2.48

Peter W. Rodino III, Esq., J.D. insider trading

AIM ImmunoTech Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 30,865 $0.41 $12,500
Purchase
Common Stock 37,879 $0.33 $12,500
Purchase
Common Stock 80,646 $0.31 $25,000
Purchase
Common Stock 8,695 $4.03 $35,041
Purchase
Common Stock 15,873 $0.63 $10,000

AIM ImmunoTech key executives

AIM ImmunoTech Inc. executives and other stock owners filed with the SEC:

  • Mr. Peter W. Rodino III, Esq., J.D. (74) Chief Operating Officer, Executive Director of Gov.al Relations, Gen. Counsel & Sec.
  • Mr. Thomas K. Equels Esq., J.D., M.S. (72) Executive Vice Chairman, Chief Executive Officer & Pres
  • Ms. Ellen M. Lintal (66) Chief Financial Officer & Chief Accounting Officer